Anti-Rh(c), "little c," isoimmunization: the role of rHuEpo in preventing late anemia.
The overall prevalence of non-Rh-D isoimmunization seems to lie between 0.15% and 1.1%. Anti-Rh(c) alloimmunization, "little c," occurs in 0.07% of pregnancies and shows a quite broad clinical presentation. Late anemia is a frequent problem occurring in the setting of isoimmunization. It occurs more frequently after intrauterine blood transfusions or exsanguinotransfusion, and it can be thought as a hyporegenerative anemia. The authors describe the use of human recombinant erythropoietin in preventing late anemia in a case of anti-Rh(c) isoimmunization. The use of human recombinant erythropoietin is a valid tool for preventing late-onset anemia due to either anti-Rh-D or non-anti-Rh-D isoimmunization.
Department of Pediatrics, Division of Neonatology, Catholic University of the Sacred Heart, Rome, Italy. zuppaaa@rm.unicatt.it
Antonio A
AA
Zuppa
Valentina
V
Cardiello
Giovanni
G
Alighieri
Francesco
F
Cota
Annamaria
A
D'Antuono
Riccardo
R
Riccardi
Piero
P
Catenazzi
Costantino
C
Romagnoli
D000740:Anemia / Q000517:prevention & control*; D001805:Blood Transfusion, Intrauterine; D027682:Cation Transport Proteins; D004899:Erythroblastosis, Fetal / Q000097:blood; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008562:Membrane Glycoproteins; D011994:Recombinant Proteins / Q000627:therapeutic use; D012203:Rh Isoimmunization / Q000097:blood / Q000150:complications*
D027682:Cation Transport Proteins; D008562:Membrane Glycoproteins; C413213:RHCG protein, human; D011994:Recombinant Proteins; D004921:Erythropoietin